What is the difference between a transudate and an exudate?

A transudate is a protein-poor fluid that accumulates when hydrostatic or oncotic pressures are altered while the pleura stays intact (for example in heart failure), whereas an exudate is a protein-rich fluid arising from local inflammation, infection, or malignancy. Light's criteria are used to tell them apart.

Why is pleural fluid sampled?

Analysing pleural fluid — its protein and LDH, cell count, cytology, and microbiology — helps classify the effusion and often identifies the underlying cause, which is why thoracentesis is central to the evaluation of an undiagnosed effusion.

Pleural Effusion

A pleural effusion is an abnormal accumulation of fluid in the pleural space, the thin gap between the membrane covering the lung and the membrane lining the chest wall. It is one of the most common manifestations of pleural disease and is a sign of an underlying process — cardiac, infectious, malignant, or otherwise — rather than a disease in its own right.

Definition

A pleural effusion is the presence of an abnormal quantity of fluid in the pleural cavity, classified as a transudate (a protein-poor ultrafiltrate reflecting altered hydrostatic or oncotic pressures) or an exudate (a protein-rich fluid reflecting increased capillary permeability or impaired lymphatic clearance).

Scope

This topic covers what a pleural effusion is, the transudate-versus-exudate framework used to narrow its cause, the principal causes in each category, and the diagnostic role of pleural fluid analysis. It is a reference and educational entry on the concept and its evaluation, not a protocol for managing fluid in an individual patient.

Core questions

Is the effusion a transudate or an exudate?
What underlying systemic or local process is producing the fluid?
What information does pleural fluid analysis (cell count, chemistry, cytology, microbiology) add?
Is the effusion benign, infected, or malignant?

Key concepts

Transudate versus exudate
Light's criteria (pleural-to-serum protein and LDH ratios)
Thoracentesis and pleural fluid analysis
Heart failure as a leading transudative cause
Parapneumonic effusion
Malignant pleural effusion
Pleural fluid pH, glucose, and LDH

Mechanisms

Pleural fluid is normally produced by filtration from the parietal pleural microvessels and reabsorbed by parietal pleural lymphatics. A transudate accumulates when systemic factors — raised systemic or pulmonary venous pressure, or low plasma oncotic pressure — shift this balance toward filtration while the pleural membranes remain intact, as in heart failure or hypoalbuminaemia. An exudate accumulates when local disease increases capillary permeability or blocks lymphatic drainage, as in infection, malignancy, or pulmonary embolism. Light's criteria separate the two: an effusion is classified as exudative if the pleural-fluid-to-serum protein ratio exceeds 0.5, the pleural-fluid-to-serum LDH ratio exceeds 0.6, or pleural fluid LDH exceeds two-thirds of the upper limit of normal serum LDH.

Clinical relevance

Determining whether an effusion is transudative or exudative is the first analytic step that narrows a broad differential and directs further investigation, and pleural fluid analysis frequently establishes the diagnosis. This entry explains the conceptual framework and is not a source of decision thresholds for sampling, drainage, or treatment in a specific patient.

Epidemiology

Pleural effusion is common, and its leading causes in many settings are congestive heart failure (typically transudative) and pneumonia and malignancy (typically exudative); the relative frequency of each cause depends on the population studied. Malignant pleural effusion is an important exudative cause and is the subject of dedicated society guidance.

Evidence & guidelines

Light's 1972 criteria remain the reference standard for separating transudates from exudates. For malignant pleural effusion, the joint European Respiratory Society and European Association for Cardio-Thoracic Surgery statement (Bibby et al., 2018) synthesises the evidence, and randomised data such as the TIME2-type comparison of indwelling pleural catheters with talc pleurodesis (Bhatnagar et al., 2018) inform how recurrent effusions are managed. Guideline recommendations change over time and are summarised here for orientation only.

History

Before 1972 the separation of pleural fluid into transudate and exudate relied on inconsistent single measurements such as specific gravity. Light and colleagues' combined-criteria approach gave the distinction a reproducible, multi-test basis that has endured for half a century and structures the modern evaluation of effusions.

Debates

How should an effusion misclassified by Light's criteria be handled?: Light's criteria are sensitive for exudates but can misclassify some transudates (for example in diuretic-treated heart failure) as exudates; supplementary measures such as the serum-to-pleural-fluid albumin gradient are debated as ways to reduce this misclassification.

Key figures

Richard W. Light
David Feller-Kopman

Seminal works

light-1972
feller-kopman-2018

Frequently asked questions

What is the difference between a transudate and an exudate?: A transudate is a protein-poor fluid that accumulates when hydrostatic or oncotic pressures are altered while the pleura stays intact (for example in heart failure), whereas an exudate is a protein-rich fluid arising from local inflammation, infection, or malignancy. Light's criteria are used to tell them apart.
Why is pleural fluid sampled?: Analysing pleural fluid — its protein and LDH, cell count, cytology, and microbiology — helps classify the effusion and often identifies the underlying cause, which is why thoracentesis is central to the evaluation of an undiagnosed effusion.